Drug news
NEPA is filed at FDA by Helsinn/Eisai for Nausea
The FDA has accepted for review the submission of the New Drug Application (NDA) for the investigational oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA) from Eisai/Helsinn, for prevention of acute and delayed chemotherapy-induced Nausea and Vomiting (CINV) following both highly and moderately emetogenic chemotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.